Opus Genetics (IRD) Operating Margin (2010 - 2026)
Opus Genetics' (IRD) quarterly Operating Margin came in at 665.92% in Q1 2026, down 43872.0% year-on-year from N/an in Q1 2025, and down 124.73% on a QoQ basis from 296.33% in Q4 2025.
Opus Genetics (IRD) Operating Margin (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 8 years of Operating Margin data on file, last reported at 665.92% in Q1 2026.
- On a quarterly basis, Operating Margin fell 43872.0% year-over-year to 665.92% in Q1 2026; TTM through Mar 2026 was 359.13%, a 11187.0% increase from a year earlier, with the FY2025 full-year figure at 271.9%, up 29282.0% from the prior year.
- Operating Margin for Q1 2026 stood at 665.92%, down from 296.33% in the prior quarter.
- Over the last five years, Operating Margin for IRD reached as high as 85.85% in Q4 2022 and fell as low as 883.98% in Q4 2024.
- Historically, Operating Margin has averaged 338.42% across 5 years, with a median of 302.67% in 2025.
- Across the five-year window, Operating Margin plunged 60224 bps in 2024 and jumped 58766 bps in 2025, its largest moves.
- Year by year, Operating Margin stood at 85.85% in 2022, then slumped by 474 bps to 321.05% in 2023, then plunged by 175 bps to 883.98% in 2024, then soared by 66 bps to 296.33% in 2025, then plunged by 125 bps to 665.92% in 2026.
- Per Business Quant data, the three most recent Operating Margin figures were 665.92% in Q1 2026, 296.33% in Q4 2025, and 269.93% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Opus Genetics | 263.72 Mn | 203.72 Mn | - | -665.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -665.92% |
| Dec 31, 2025 | -296.33% |
| Sep 30, 2025 | -269.93% |
| Jun 30, 2025 | -309.02% |
| Mar 31, 2025 | -227.21% |
| Dec 31, 2024 | -883.98% |
| Sep 30, 2024 | -207.11% |
| Jun 30, 2024 | -748.92% |
| Mar 31, 2024 | -450.50% |
| Dec 31, 2023 | -321.05% |
| Sep 30, 2023 | 53.51% |
| Jun 30, 2023 | -146.68% |
| Mar 31, 2023 | -350.54% |
| Dec 31, 2022 | 85.85% |
| Sep 30, 2021 | -865.44% |
| Jun 30, 2021 | -7,137.00% |
| Mar 31, 2020 | -237.83% |
| Jun 30, 2010 | -17,008.07% |